Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab Therapeutic Strategies in Moderate-to-Severe Plaque Psoriasis
2023-508424-34-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in plaque psoriasis (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Proportion of subjects with absolute PASI score <3 at week 68 in study groups 2a and 2b. Started Jun 2024; status: completed.
02
Drugs
guselkumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2023-508424-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508424-34-00.